Comments to FDA: Remote Regulatory Assessments Draft Guidance Share page: Docket Number: FDA-2022-D-0810 CHPA appreciates the opportunity to provide comments on FDA Remote Regulatory Assessments Draft Guidance. Download Document Issues: OTC Medicines Dietary Supplements OTC Medical Devices Related Posts Press Releases and Statements CHPA Applauds White House Executive Order Prioritizing Lower Drug Costs and Access to Self-Care Apr 17, 2025 Press Releases and Statements CHPA Responds to Section 232 Investigation on Pharmaceuticals Apr 15, 2025 Press Releases and Statements CHPA Commends Lawmakers for Urging FDA to Protect the Rx-OTC-Switch Pathway Apr 11, 2025